Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of all races between 18 and 60 years of age~* Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg. This will allow us to include subjects with pre-hypertension.~* Able and willing to provide informed consent~Exclusion Criteria:~* Pregnancy or breast feeding~* Current smokers or history of heavy smoking (\>2 packs/day)~* History of alcohol or drug abuse~* Previous allergic reaction to study medications~* Evidence of type I or type II diabetes (i.e. fasting glucose \>126 mg/dl, use of anti-diabetic medications)~* Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy~* History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack~* History or presence of immunological or hematological disorders~* Impaired hepatic function \[aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) \> 2.0 x upper limit of normal range\]~* Impaired renal function (serum creatinine \>1.5 mg/dl)~* Anemia (hemoglobin \<13.5 g/dl in males or \<12.5 g/dl in females)~* Treatment with phosphodiesterase 5 inhibitors~* Treatment with anticoagulants~* Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)~* Treatment with any investigational drug in the 1 month preceding the study~* Inability to give, or withdraw, informed consent~* Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e. clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Intact Study Day (Type: ACTIVE_COMPARATOR): Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
- Autonomic Blockade Study Day (Type: EXPERIMENTAL): Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.

Based on this trial design, predict the completion outcome and termination type (if applicable).